Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Mol Med (Berl). 2019 Dec;97(12):1695-1710. doi: 10.1007/s00109-019-01847-0. Epub 2019 Nov 15.
Of all genetic mutations causing human disease, premature termination codons (PTCs) that result from splicing defaults, insertions, deletions, and point mutations comprise around 30%. From these mutations, around 11% are a substitution of a single nucleotide that change a codon into a premature termination codon. These types of mutations affect several million patients suffering from a large variety of genetic diseases, ranging from relatively common inheritable cancer syndromes to muscular dystrophy or very rare neuro-metabolic disorders. Over the past three decades, genetic and biochemical studies have revealed that certain antibiotics and other synthetic molecules can act as nonsense mutation readthrough-inducing drugs. These compounds bind a specific site on the rRNA and, as a result, the stop codon is misread and an amino acid (that may or may not differ from the wild-type amino acid) is inserted and translation occurs through the premature termination codon. This strategy has great therapeutic potential. Unfortunately, many readthrough agents are toxic and cannot be administered over the extended period usually required for the chronic treatment of genetic diseases. Furthermore, readthrough compounds only restore protein production in very few disease models and the readthrough levels are usually low, typically achieving no more than 5% of normal protein expression. Efforts have been made over the years to overcome these obstacles so that readthrough treatment can become clinically relevant. Here, we present the creation of a stable cell line system that constitutively expresses our dual-reporter vector harboring two cancer initiating nonsense mutations in the adenomatous polyposis coli (APC) gene. This system will be used as an improved screening method for isolation of new nonsense mutation readthrough inducers. Using these cell lines as well as colorectal cancer cell lines, we demonstrate that serum starvation enhances drug-induced readthrough activity, an observation which may prove beneficial in a therapeutic scenario that requires higher levels of the restored protein. KEY MESSAGES: Nonsense mutations affects millions of people worldwide. We have developed a nonsense mutation read-through screening tool. We find that serum starvation enhances antibiotic-induced nonsense mutation read-through. Our results suggest new strategies for enhancing nonsense mutation read-through that may have positive effects on a large number of patients.
所有导致人类疾病的基因突变中,大约有 30%是由于剪接错误、插入、缺失和点突变导致的提前终止密码子(PTC)。在这些突变中,大约有 11%是单个核苷酸的替换,使密码子变成提前终止密码子。这些类型的突变影响了数百万患有各种遗传疾病的患者,从相对常见的遗传性癌症综合征到肌肉营养不良症或非常罕见的神经代谢紊乱。在过去的三十年中,遗传和生化研究揭示了某些抗生素和其他合成分子可以作为无意义突变通读诱导药物。这些化合物结合在 rRNA 的特定部位,结果是终止密码子被误读,一个氨基酸(可能与野生型氨基酸不同)被插入,并且通过提前终止密码子进行翻译。这种策略具有巨大的治疗潜力。不幸的是,许多通读剂是有毒的,并且不能在通常用于慢性治疗遗传疾病所需的延长时间内给药。此外,通读化合物仅在极少数疾病模型中恢复蛋白质产生,并且通读水平通常较低,通常仅达到正常蛋白质表达的 5%左右。多年来,人们一直在努力克服这些障碍,以使通读治疗能够具有临床相关性。在这里,我们展示了一种稳定细胞系系统的创建,该系统持续表达我们的双报告载体,该载体在腺瘤性结肠息肉病(APC)基因中含有两个致癌起始的无意义突变。该系统将被用作分离新的无意义突变通读诱导剂的改进筛选方法。使用这些细胞系以及结直肠癌细胞系,我们证明血清饥饿增强了药物诱导的通读活性,这一观察结果在需要更高水平恢复蛋白的治疗情况下可能是有益的。关键信息:无意义突变影响全球数百万人。我们已经开发了一种无意义突变通读筛选工具。我们发现血清饥饿增强了抗生素诱导的无意义突变通读。我们的结果为增强无意义突变通读提供了新的策略,这可能对大量患者产生积极影响。